BioCatalystWatch
HCMWorkspace / HCM / OverviewCompany library
Price
Market cap
Next catalystExpected 2026IMG-007 · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

sovleplenib (HMPL-523)

Syk

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

sovleplenib (HMPL-523)

Syk

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

VEGFR1 × VEGFR2 × VEGFR3

PreINDP1P2P3FilingApproved

VEGFR1 × VEGFR2 × VEGFR3

PreINDP1P2P3FilingApproved

Partner / License out

RIPK1

PreINDP1P2P3FilingApproved
IMG-007

OX40 (CD134)

PreINDP1P2P3FilingApproved

BTK

PreINDP1P2P3FilingApproved

CSF-1R

PreINDP1P2P3FilingApproved
IMG-007

OX40 (CD134)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Approved / commercial

VEGFR1 × VEGFR2 × VEGFR3

PreINDP1P2P3FilingApproved

SULANDA® (surufatinib)

VEGFR × FGFR × CSF-1R

Approved

PreINDP1P2P3FilingApproved

MET

PreINDP1P2P3FilingApproved

MET

Approved

PreINDP1P2P3FilingApproved

VEGFR1 × VEGFR2 × VEGFR3

Approved

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

HCM PR & News

PR & News

HCM SEC archive